Arrowhead Pharmaceuticals/$ARWR
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting cardiovascular, Cardiometabolic, Central Nervous System, Pulmonary, Liver, Muscular, and Complement Mediated Disease. It majority products are liver disease curable.
Ticker
$ARWR
Sector
Primary listing
Employees
609
Headquarters
Website
ARWR Metrics
BasicAdvanced
$4.1B
-
-$1.14
0.95
-
Price and volume
Market cap
$4.1B
Beta
0.95
52-week high
$29.80
52-week low
$9.57
Average daily volume
2.7M
Financial strength
Current ratio
4.868
Quick ratio
4.667
Long term debt to equity
128.178
Total debt to equity
115.54
Interest coverage (TTM)
-1.31%
Profitability
EBITDA (TTM)
-85.396
Gross margin (TTM)
100.00%
Net profit margin (TTM)
-25.90%
Operating margin (TTM)
-18.84%
Effective tax rate (TTM)
-1.25%
Revenue per employee (TTM)
$940,000
Management effectiveness
Return on assets (TTM)
-5.96%
Return on equity (TTM)
-37.11%
Valuation
Price to revenue (TTM)
6.763
Price to book
7.86
Price to tangible book (TTM)
7.86
Price to free cash flow (TTM)
-219.899
Free cash flow yield (TTM)
-0.45%
Free cash flow per share (TTM)
-0.135
Growth
Revenue change (TTM)
2,816.21%
Earnings per share change (TTM)
-75.59%
3-year revenue growth (CAGR)
31.86%
10-year revenue growth (CAGR)
107.78%
3-year earnings per share growth (CAGR)
-8.08%
10-year earnings per share growth (CAGR)
-3.39%
What the Analysts think about ARWR
Analyst ratings (Buy, Hold, Sell) for Arrowhead Pharmaceuticals stock.
Bulls say / Bears say
The licensing agreement with Novartis brings Arrowhead $200 million upfront and the potential for up to $2 billion in milestone payments for ARO-SNCA, greatly reducing financial uncertainty and highlighting the value of Arrowhead’s RNAi platform. (Reuters)
The Novartis agreement includes options for further collaborations using Arrowhead’s RNA-targeting technology beyond the current ARO-SNCA program, demonstrating broad commercial potential for its TRiMTM platform. (Reuters)
Arrowhead expects to receive $300 million in near-term milestone payments from Sarepta by the end of the year as ARO-DM1 reaches enrollment targets, further strengthening its cash position. (Reuters)
Arrowhead’s dependence on milestone payments from Sarepta for the ARO-DM1 collaboration exposes it to counterparty risk; Sarepta could delay or terminate payments if clinical issues arise. (Reuters)
ARO-SNCA, the main asset involved in the Novartis deal, is still in preclinical development and has not yet begun trials in humans, so Arrowhead faces significant early-stage development risks. (Reuters)
Analysts emphasize Arrowhead would struggle to advance the Sarepta-licensed therapies on its own without the partnership, significantly limiting its strategic options. (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 5 Sept 2025.
ARWR Financial Performance
Revenues and expenses
ARWR Earnings Performance
Company profitability
ARWR News
AllArticlesVideos
Arrowhead Pharmaceuticals Files Complaint for Declaratory Judgment Against Ionis Pharmaceuticals
Business Wire2 days ago
Arrowhead Pharmaceuticals Requests Regulatory Clearance to Initiate Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer's Disease and Other Tauopathies
Business Wire3 days ago
Arrowhead Pharmaceuticals and Novartis Enter into a Global License and Collaboration Agreement
Business Wire2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Arrowhead Pharmaceuticals stock?
Arrowhead Pharmaceuticals (ARWR) has a market cap of $4.1B as of September 13, 2025.
What is the P/E ratio for Arrowhead Pharmaceuticals stock?
The price to earnings (P/E) ratio for Arrowhead Pharmaceuticals (ARWR) stock is 0 as of September 13, 2025.
Does Arrowhead Pharmaceuticals stock pay dividends?
No, Arrowhead Pharmaceuticals (ARWR) stock does not pay dividends to its shareholders as of September 13, 2025.
When is the next Arrowhead Pharmaceuticals dividend payment date?
Arrowhead Pharmaceuticals (ARWR) stock does not pay dividends to its shareholders.
What is the beta indicator for Arrowhead Pharmaceuticals?
Arrowhead Pharmaceuticals (ARWR) has a beta rating of 0.95. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.